small molecule

JAYPIRCA

PIRTOBRUTINIB

Loss of exclusivitySeptember 2041latest FDA-listed patent expiry

CompanyLoxo Oncology →See this company's full patent-cliff portfolio

Drug detail

Brand name	JAYPIRCA
Active ingredient	PIRTOBRUTINIB
Strength	50MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	January 2023
Marketing status	RX

Listed patents

Patent	Expires	Type
12109193	September 2041	product
12268666	July 2039	product
10464905	December 2036	use U-4362
10918622	December 2036	use U-4362
10342780	December 2036	substance, product
12220401	December 2036	substance, product
10695323	December 2036	substance, product

Regulatory exclusivity

Code	Expires
ODE-518	December 2032
ODE-451	December 2030
ODE-424	January 2030
I-981	December 2028
NCE	January 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Loxo Oncology